Wave Life Sciences Ltd.

With 48-week data from a Phase II open-label trial in Duchenne muscular dystrophy (DMD) showing an advancement in clinical benefit beyond what a 24-week readout showed last year, Wave Life Sciences sa

Although GLP-1 agonists for obesity have made a significant difference for patients and brought in a financial windfall for their manufacturers, there remains a lingering problem of the drugs reducing

Wave Life Sciences is developing a new weight loss candidate, WVE-007, which it believes could not only avoid muscle-loss problems but also the loss of pleasure in eating that some patients report

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Angelini Licenses Cureverse’s Nov